Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

36.26USD
23 Feb 2018
Change (% chg)

$0.52 (+1.45%)
Prev Close
$35.74
Open
$35.93
Day's High
$36.30
Day's Low
$35.83
Volume
5,345,691
Avg. Vol
6,195,209
52-wk High
$39.43
52-wk Low
$31.67

Select another date:

Fri, Feb 23 2018

BRIEF-Pfizer Receives Positive CHMP Opinion For Two Hematology Medicines

* PFIZER RECEIVES POSITIVE CHMP OPINION FOR TWO HEMATOLOGY MEDICINES, MYLOTARG™ AND BOSULIF®

BRIEF-Albert Bourla Elected To Pfizer’S Board Of Directors

* PFIZER INC - ‍BOURLA IS CURRENTLY COO OF PFIZER​ Source text for Eikon: Further company coverage:

BRIEF-Spark Therapeutics Enters Into A Spk-9001 Manufacture And Supply Agreement With Pfizer

* SPARK THERAPEUTICS INC - ON FEB 16, CO ENTERED INTO A SPK-9001 MANUFACTURE AND SUPPLY AGREEMENT WITH PFIZER - SEC FILING

BRIEF-Reckitt CEO bullish on consumer health, no comment on Pfizer

* RECKITT BENCKISER CEO SAYS NO COMMENT ON PFIZER CONSUMER HEALTH AUCTION

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

FRANKFURT Merck KGaA and Pfizer received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies.

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

FRANKFURT, Feb 15 Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.

BRIEF-Nestle declines to comment on interest in Pfizer, Merck units

* CEO SAYS NO COMMENT ON INTEREST IN PFIZER, MERCK CONSUMER HEALTH UNITS, BUT IS GENERALLY INTERESTED IN EXPANDING ITS CONSUMER HEALTH BUSINESS

BRIEF-Pfizer Receives Breakthrough Therapy Designation From FDA For Atopic Dermatitis Treatment, PF-04965842

* PFIZER RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR PF-04965842, AN ORAL JAK1 INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS Source text for Eikon: Further company coverage:

U.S. investment adviser gets prison for insider trading on Pfizer-King deal

NEW YORK A Long Island, New York, investment adviser was sentenced to six months in prison on Monday after he pleaded guilty to insider trading in connection with Pfizer Inc's $3.6 billion acquisition of King Pharmaceuticals Inc.

BRIEF-‍NetVation DL Medicine announces research collaboration with Pfizer Inc

* ‍NETVATION DL MEDICINE -ENTERED INTO A TWO-YEAR RESEARCH COLLABORATION WITH PFIZER INC

Select another date: